Luke Evnin

Medical Portfolio Management LLC is a private company based in New York, NY.

Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA.

Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria.

Idun Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of human therapeutics to control apoptosis. The company was founded by John C. Reed, Robert H. Horvitz, and Lawrence C. Fritz in March 1993 and is headquartered in San Diego, CA.

Innovative Spinal Technologies, Inc. (IST) develops spinal technology products and surgical protocols. Its products include Axient, Paramount PSS, Paramount VBR, and Cordant ACP. The company was founded in 2002 by Stephen Hochschuler and Barton Sachs and is headquartered in Mansfield, MA.

Potenza Therapeutics, Inc. develops oncology programs and mechanisms for tumors detection. It is focusing on the discovery and development of novel immune-oncology therapeutics: molecules that stimulate the power of the immune system to fight cancer. The company was founded by Drew M. Pardoll and Daniel J. Hicklin in 2014 and is headquartered in Cambridge, MA.

Accel Partners LLC is a venture capital firm founded in 1987 by Jim Swartz and Arthur Patterson. The firm is headquartered in California, the US.

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.

Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom.

Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products.

Part of MPM BioImpact, Inc, MPM Asset Management LLC is a company that provides venture capital. The company is based in Boston, MA.

BioValve Technologies, Inc. develops new chemical entities for the treatment of central nervous system conditions. It offers various dopamine agonists for treatment of parkinson's disease and schizophrenia; and novel disposable pharmaceutical delivery systems. The company was founded by Robert R. Gonnelli in 1998 and is headquartered in Parsippany, NJ.

Restore Medical developed, manufactured and marketed pillar palatal implant systems used for the treatment of soft palate components of sleeps disordered breathing, obstructive sleep apnea, and snoring. The company was founded in 1999 and was headquartered in St. Paul, MN.

EnteroMedics, Inc. is a medical device company, which in the design, and development of devices that use neuroblocking technology to treat obesity,metabolic diseases, and other gastrointestinal disorders. It offers vBlock system, which is a therapy to limit expansion of hte stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The company was founded by Mark B. Knudson, Robert S. Nickoloff, Timothy R. Conrad, Katherine S. Tweden and Richard R. Wilson on December 19, 2002 and is headquartered in St. Paul, MN.

The Scleroderma Research Foundation is a non-profit organization that funds research for scleroderma, a potentially life-threatening illness. The non-profit company is based in San Francisco, CA. Established in 1987 by a patient-turned-activist, the foundation is the largest investor in scleroderma research. The foundation's goal is to find a cure for the disease by bringing together the best minds in science. The SRF has invested over $39 million dollars to date in scleroderma research, funding and facilitating research at top institutions such as Johns Hopkins University School of Medicine, Stanford University, and the University of California.

NeuroTherapeutics Pharma, Inc. is a biopharmaceutical company focused on developing therapies for diseases associated with central nervous system hyper-excitability. It is developing compounds that decrease or eliminate aberrant excitatory discharges by working through a new mechanism of action. The firm's proprietary molecules target a novel molecular site that will create a pipeline of potential new treatments for multiple CNS disorders. The company's lead compound, NTP-2014, has exhibited excellent efficacy results in multiple preclinical models of epilepsy, acute and neuropathic pain. NeuroTherapeutics Pharma was founded in 2006 and is headquartered in Chicago, IL.

Otix Global was designed, manufactured and marketed digital hearing care solutions. It had offered hearing aids and wireless accessories including mics, remote controls, television adapters and phone adapters. The company was founded in 1991 and headquartered in Salt Lake City, UT.

CoStim Pharmaceuticals, Inc. operates as a biotech company which develops biologics for oncology indications. It offers therapies which target immune checkpoint inhibitors for novel treatment. The company was founded on February 01, 2013 and is headquartered in Boston, MA.

Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom.

Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA.

Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA.

Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA.

Trieza Therapeutics, Inc. provides pharmaceutical services. It engages in the developing immunomodulatory oncolytic viruses for the treatment of cancer. The company is headquartered in Cambridge, MA.

Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA.

Redona Therapeutics, Inc.operates as a biotechnology company focused on the modulation of non- RNA (ncRNA) function to treat cancer and other human diseases. It uses small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. The company was founded by George Daley, Richard Gregory, Frank Slack, and Piotr Sliz and is headquartered in Watertown, MA.

Frontier Medicines Corp. develops medicines that redefine the course of debilitating diseases. The company was founded by Chris Varma, Daniel K. Nomura and Roberto Zoncu in 2018 and is headquartered in South San Francisco, CA.

Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA.

Turmeric Acquisition Corp. operates as a blank check company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on August 28, 2020 and is headquartered in Cambridge, MA.

Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021.

Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation.